Altogether, these results encourage implication of ATX-LPAR1 combination therapy or dual inhibitors of ATX-LPAR1 as treatment for various cancers, IPF and rheumatoid arthritis. The gene discussed is LPAR1; the disease is rheumatoid arthritis.